Pulsed electric field ablation for chronic bronchitis in COPD

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, parallel-group, sham-controlled multicenter trial that will enroll 210 adults with moderate to severe chronic bronchitis related to COPD and randomize them 2:1 to active pulsed electric field ablation or a sham procedure. The device being tested is a pulsed electric field ablation system manufactured by Suzhou Hengruihongyuan Medical Technology Co., Ltd. Eligible participants must meet symptom thresholds (CAT ≥ 10, SGRQ ≥ 25), airflow obstruction criteria (FEV1/FVC < 0.70 and post-bronchodilator FEV1 ≥ 30% predicted), and be receiving guideline-directed long-acting bronchodilator therapy. The trial will collect safety and effectiveness outcomes focused on symptom relief and quality of life compared to the sham procedure.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Subject's age is ≥35 years and ≤80 years.
2. Patient has chronic bronchitis, defined as productive cough for three months in each of two successive years, whereas other causes of productive cough have been ruled out.
3. Patient has a CAT score ≥ 10.
4. Patient has an SGRQ score ≥ 25.
5. Patient's responses to the first two questions of the CAT instrument sum to ≥ 7 points or the sum is 6 points and the patient's total CAT score is \> 20 points.
6. Patient has FEV1/FVC \< 0.70.
7. Patient has a pre-procedure post-bronchodilator FEV1 percent predicted of ≥ 30%.
8. Patient is receiving guideline directed pharmacotherapy which includes one or more long acting bronchodilator (LAMA, LABA) with or without an inhaled corticosteroid for at least 8 weeks prior to randomization, unless the patient has attempted such therapy within the past 1 year without significant clinical response or had an adverse reaction.
9. In the opinion of the Primary investigator, patient is able to undergo 2 bronchoscopies under general anesthesia and is able to adhere to the study follow-up schedule.
10. Informed consent signed by the patient or legal representative.

Exclusion Criteria:

1. Patient has known unresolved lower respiratory tract infection (e.g., pneumonia, mycobacterium avium-intracellulare infection (MAI), fungus, tuberculosis).
2. Patient has a steroid-dependent condition requiring \>10 mg of oral corticosteroid per day.
3. Patient has any implantable electronic device (e.g., pacemaker, cardioverter defibrillator) that cannot be turned off during the procedure.
4. Patient has a history of ventricular tachy-arrhythmia or clinically significant atrial tachyarrhythmia within the past two years, or sinus bradycardia with a heart rate of under than 45 beats per minute, unless the arrhythmia has been treated and/or patient is in regular rhythm during the screening phase.
5. Subject has lung cancer.
6. Patient has a pulmonary nodule or cavity that in the judgement of the Primary investigator may require intervention during the course of the study.
7. Patient had prior lung surgery, such as lung transplant, LVRS, lobectomy, lung implant/prosthesis, metal airway stent, valves, coils or bullectomy.
8. Patient has emphysema of greater than or equal to 50% as quantified on baseline HRCT scan as determined by the CT Core Lab.
9. Patient has asthma based on Global Initiative for Asthma (GINA) criteria.
10. Patient has clinically significant bronchiectasis influencing the patient's clinical symptoms of cough and phlegm.
11. Patient has actively smoked (including tobacco, marijuana, e-cigarettes, vaping, etc.) within the last 2 months.
12. Patient is unable to walk over 225 meters in 6 minutes.
13. Patient has a serious medical condition that, in the Primary investigator's opinion, could compromise patient safety or confound the interpretation of the patient's response to therapy (e.g., congestive heart failure, cardiomyopathy, or myocardial infarction in the past year, renal failure, liver disease, cerebrovascular accident within the past 6 months, uncontrolled diabetes (HbA1c \>8%), uncontrolled hypertension (diastolic BP \>100mmHg) or autoimmune disease requiring treatment with immunosuppressant medications or a disease requiring chemotherapy).
14. Patient has uncontrolled GERD.
15. Patient has known severe pulmonary hypertension (pulmonary artery SP ≥ 50 mmHg).
16. Patient has a known sensitivity to medication required to perform bronchoscopy (i.e., lidocaine, atropine, benzodiazepines).
17. Patient is pregnant, nursing, or planning to get pregnant during study duration.
18. Patient is currently participating in another clinical study involving an investigational product.
19. Patient is receiving anticoagulation for a cardiovascular indication and, in the Primary investigator's opinion, unable to suspend anticoagulant medications (i.e., aspirin, clopidogrel, warfarin) during bronchoscopy in accordance.
20. Patient has known airway colonization with drug-resistant bacteria such as Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus, Burkholderia cepacia complex, Mycobacterium tuberculosis, Mycobacterium abscessus, Trichoderma, or other significant fungi.

Where it's running

• Sir Run Run Shaw Hospital, affiliated with Zhejiang University School of Medicine
  Hangzhou, Zhejiang, China Recruiting
• Anhui Chest Hospital
  Hefei, Anui, China Not yet recruiting
• Affiliated Beijing Chaoyang Hospital of Capital Medical University
  Beijing, Beijing Municipality, China Not yet recruiting
• Hospital Emergency General
  Beijing, Beijing Municipality, China Not yet recruiting
• The First People's Hospital of Changzhou
  Changzhou, Jiangsu, China Not yet recruiting
• The Second Affiliated Hospital of Soochow University
  Suzhou, Jiangsu, China Not yet recruiting

Study contacts

• Study coordinator: Enguo Chen
• Email: cheneg@srrsh.com
• Phone: +86 13588706779

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Enhanced COPD care for people being checked for lung cancer

  This project will test whether finding and treating COPD early in people being checked for possible lung cancer helps symptoms, lung function, and overall care.

  Recruiting Region of Southern Denmark · Vejle · NCT07543601

• High-Flow Nasal Cannula vs Noninvasive Ventilation in COPD with Hypercapnia

  This study tests whether a high-flow nasal cannula can better support gas exchange and comfort compared with noninvasive ventilation in COPD patients with mild-to-moderate elevated CO2.

  Recruiting Mansoura University · Al Mansurah, Dakahlia Governorate · NCT07854210

• Risk-based lung cancer screening in COPD patients using ML and clinical models

  This study tests whether a PLCOm2012 risk model plus a machine learning model can spot COPD patients at high risk for lung cancer to see if they benefit from low-dose CT screening.

  Recruiting Vejle Hospital · Vejle, Region Syddanmark · NCT07848815

• Biologics for Type 2 Inflammation in Asthma and COPD in Real World

  This real-world study tests whether six biologic drugs can reduce flare-ups and improve symptoms in adults with asthma or COPD treated in routine care in China.

  Recruiting Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07823842

• Nebulized vs handheld maintenance therapy for COPD patients with limited benefit from inhalers

  This trial tests whether switching to a breath-enhanced nebulizer with similar COPD meds helps people who don’t get enough relief from their current handheld inhalers.

  Recruiting at 2 sites Phase 4 COPD Foundation · Saint Charles, Missouri and 1 other locations · NCT07816835

• New breathing tests to diagnose airway disease in hospital and community settings

  This study tests whether newer breathing tests can correctly diagnose COPD and airway disease as well as standard spirometry, using tests like capnography and oscillometry in hospital and community settings.

  Recruiting University Hospital Southampton NHS Foundation Trust · Andover, Hampshire and 1 other locations · NCT07798596

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.